{"doi":"10.21873/invivo.12676","title":"Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft","abstract":"BACKGROUND: Overexpression of mucin-5AC (MUC5AC) makes it a targetable biomarker in pancreatic cancer. The present study evaluated tumor targeting with a MUC5AC antibody conjugated to a near-infrared dye in a patient-derived orthotopic xenograft (PDOX) mouse model. MATERIALS AND METHODS: MUC5AC monoclonal antibody was conjugated to the near-infrared dye IRDye800CW to synthesize MUC5AC-IR800. PDOX models were established by implanting a high-MUC5AC-expressing patient-derived pancreatic tumor on the pancreas of nude mice. After 4 weeks of PDOX tumor growth, mice were imaged after receiving MUC5AC-IR800 (75 μg) intravenously. RESULTS: In the PDOX models, MUC5AC-IR800 selectively and brightly targeted the pancreatic tumor (tumor to background ratio: 2.46±0.465). CONCLUSION: MUC5AC-IR800 provides distinct visualization of pancreatic tumors. MUC5AC-IR800 may be used clinically in the future to improve pancreatic cancer resection. This novel fluorescent probe is also promising for targeting of pre-malignant pancreatic lesions with subsequent resection under fluorescence guidance.","journal":"In Vivo","year":2021,"id":182471,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9602,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":227846,"name":"Hannah M. Hollandsworth","orcid":"0000-0002-8867-6835","position":1,"is_corresponding":false},{"id":428098,"name":"Hiroto Nishino","orcid":"0000-0002-7377-9997","position":2,"is_corresponding":false},{"id":432271,"name":"Siamak Amirfakhri","orcid":"0000-0002-5534-1043","position":3,"is_corresponding":false},{"id":399591,"name":"Thinzar M. Lwin","orcid":"0000-0003-1820-088X","position":4,"is_corresponding":false},{"id":250597,"name":"Andrew M. Lowy","orcid":"0000-0002-7106-0735","position":5,"is_corresponding":false},{"id":255900,"name":"Sukhwinder Kaur","orcid":"0000-0002-8976-0916","position":6,"is_corresponding":false},{"id":404644,"name":"Gopalakrishnan Natarajan","orcid":"0000-0001-8813-764X","position":7,"is_corresponding":false},{"id":255899,"name":"Kavita Mallya","orcid":"0000-0001-6562-5827","position":8,"is_corresponding":false},{"id":370841,"name":"Robert M. Hoffman","orcid":"0000-0002-0049-0041","position":9,"is_corresponding":false},{"id":106461,"name":"Surinder K. Batra","orcid":"0000-0001-9470-9317","position":10,"is_corresponding":false},{"id":399592,"name":"Michael Bouvet","orcid":"0000-0002-0086-2159","position":11,"is_corresponding":false},{"id":432270,"name":"Michael A. Turner","orcid":"0000-0001-8949-3136","position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-18T23:48:13.605421Z","pmid":"34972700","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}